Jones Financial Companies
PCSA icon

Jones Financial Companies’s Processa Pharmaceuticals PCSA Stock Holding History

Jones Financial Companies’s Portfolio PCSA Stock Details PCSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13 Hold
7
– – ﹤0.01% 4932
2026
Q1 		$17 Hold
7
– – ﹤0.01% 4692
2025
Q4 		$20 Sell
7
-1
-13% -$7 ﹤0.01% 4368
2025
Q3 		$40 Buy
+8
New +$42 ﹤0.01% 4186

Other funds holding PCSA

CCM
Connective Capital Management Palo Alto, California $142M AUM 51.29% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Jones Financial Companies's PCSA Position: Q2 2026 in Review

Jones Financial Companies held its Processa Pharmaceuticals (PCSA) position steady in Q2 2026 at 7 shares worth $13. The position accounts for ﹤0.01% of the portfolio, ranked #4932.

Jones Financial Companies first reported a position in PCSA in Q3 2025 and has held it in 4 quarters since. The position peaked at $40 in Q3 2025. 12 funds tracked by Wall St. Rank hold PCSA as of Q2 2026.

  • Jones Financial Companies held 7 shares of Processa Pharmaceuticals worth $13 as of Q2 2026.
  • Jones Financial Companies left its Processa Pharmaceuticals share count unchanged in Q2 2026.
  • Processa Pharmaceuticals made up ﹤0.01% of Jones Financial Companies's portfolio in Q2 2026, its #4932 holding.
  • Jones Financial Companies first reported a position in Processa Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Jones Financial Companies's Processa Pharmaceuticals position peaked at $40 in Q3 2025.
  • 12 funds tracked by Wall St. Rank held Processa Pharmaceuticals as of Q2 2026.

Based on Jones Financial Companies's 13F filing for Q2 2026, filed 14 Aug 2026.